Cargando…

Radionuclide Delivery Strategies in Tumor Treatment: A Systematic Review

The aim of this review was to assess recent progress in targeted radionuclide tumor therapy, focusing on the best delivery strategies. A literature search was conducted in PubMed, Web of Science, and Scopus using the terms “radionuclides”, “liposomes”, “avidin–biotin interaction”, “theranostic”, and...

Descripción completa

Detalles Bibliográficos
Autores principales: Poletto, Giulia, Cecchin, Diego, Bartoletti, Paola, Venturini, Francesca, Realdon, Nicola, Evangelista, Laura
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9332578/
https://www.ncbi.nlm.nih.gov/pubmed/35892711
http://dx.doi.org/10.3390/cimb44080225
_version_ 1784758682501775360
author Poletto, Giulia
Cecchin, Diego
Bartoletti, Paola
Venturini, Francesca
Realdon, Nicola
Evangelista, Laura
author_facet Poletto, Giulia
Cecchin, Diego
Bartoletti, Paola
Venturini, Francesca
Realdon, Nicola
Evangelista, Laura
author_sort Poletto, Giulia
collection PubMed
description The aim of this review was to assess recent progress in targeted radionuclide tumor therapy, focusing on the best delivery strategies. A literature search was conducted in PubMed, Web of Science, and Scopus using the terms “radionuclides”, “liposomes”, “avidin–biotin interaction”, “theranostic”, and “molecular docking”. The 10 year filter was applied, except for the avidin–biotin interaction. Data were retrieved from both preclinical and clinical settings. Three targeting strategies were considered: pretargeting, liposomes, and ligands. Pretargeting can be achieved by exploiting the avidin–biotin interaction. This strategy seems very promising, although it has been investigated mainly in resectable tumors. Radiolabeled liposomes have attracted new interest as probes to identify the most suitable patients for treatment with liposomal formulations of common chemotherapeutics. The use of ligands for the delivery of radiotherapeutics to a specific target is still the most appealing strategy for treating tumors. The most appropriate ligand can be identified by virtually simulating its interaction with the receptor. All strategies showed great potential for use in targeted radionuclide therapy, but they also have numerous drawbacks. The most promising option is probably the one based on the use of new ligands.
format Online
Article
Text
id pubmed-9332578
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-93325782022-07-29 Radionuclide Delivery Strategies in Tumor Treatment: A Systematic Review Poletto, Giulia Cecchin, Diego Bartoletti, Paola Venturini, Francesca Realdon, Nicola Evangelista, Laura Curr Issues Mol Biol Review The aim of this review was to assess recent progress in targeted radionuclide tumor therapy, focusing on the best delivery strategies. A literature search was conducted in PubMed, Web of Science, and Scopus using the terms “radionuclides”, “liposomes”, “avidin–biotin interaction”, “theranostic”, and “molecular docking”. The 10 year filter was applied, except for the avidin–biotin interaction. Data were retrieved from both preclinical and clinical settings. Three targeting strategies were considered: pretargeting, liposomes, and ligands. Pretargeting can be achieved by exploiting the avidin–biotin interaction. This strategy seems very promising, although it has been investigated mainly in resectable tumors. Radiolabeled liposomes have attracted new interest as probes to identify the most suitable patients for treatment with liposomal formulations of common chemotherapeutics. The use of ligands for the delivery of radiotherapeutics to a specific target is still the most appealing strategy for treating tumors. The most appropriate ligand can be identified by virtually simulating its interaction with the receptor. All strategies showed great potential for use in targeted radionuclide therapy, but they also have numerous drawbacks. The most promising option is probably the one based on the use of new ligands. MDPI 2022-07-22 /pmc/articles/PMC9332578/ /pubmed/35892711 http://dx.doi.org/10.3390/cimb44080225 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Review
Poletto, Giulia
Cecchin, Diego
Bartoletti, Paola
Venturini, Francesca
Realdon, Nicola
Evangelista, Laura
Radionuclide Delivery Strategies in Tumor Treatment: A Systematic Review
title Radionuclide Delivery Strategies in Tumor Treatment: A Systematic Review
title_full Radionuclide Delivery Strategies in Tumor Treatment: A Systematic Review
title_fullStr Radionuclide Delivery Strategies in Tumor Treatment: A Systematic Review
title_full_unstemmed Radionuclide Delivery Strategies in Tumor Treatment: A Systematic Review
title_short Radionuclide Delivery Strategies in Tumor Treatment: A Systematic Review
title_sort radionuclide delivery strategies in tumor treatment: a systematic review
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9332578/
https://www.ncbi.nlm.nih.gov/pubmed/35892711
http://dx.doi.org/10.3390/cimb44080225
work_keys_str_mv AT polettogiulia radionuclidedeliverystrategiesintumortreatmentasystematicreview
AT cecchindiego radionuclidedeliverystrategiesintumortreatmentasystematicreview
AT bartolettipaola radionuclidedeliverystrategiesintumortreatmentasystematicreview
AT venturinifrancesca radionuclidedeliverystrategiesintumortreatmentasystematicreview
AT realdonnicola radionuclidedeliverystrategiesintumortreatmentasystematicreview
AT evangelistalaura radionuclidedeliverystrategiesintumortreatmentasystematicreview